Skip to main content
TISSUE REPAIR LTD logo

TISSUE REPAIR LTD — Investor Relations & Filings

Ticker · TRP ISIN · AU0000180887 ASX Professional, scientific and technical activities
Open in API
Filings indexed 139 across all filing types
Latest filing 2023-07-30 Interim / Quarterly Rep…
Country AU Australia
Listing ASX TRP

About TISSUE REPAIR LTD

https://tissuerepair.com.au/

Tissue Repair Ltd is a clinical-stage biopharmaceutical company focused on the development of advanced wound healing and skin repair agents. The company’s core technology centers on Glucoprime, a proprietary yeast-derived beta-glucan designed to stimulate the innate immune system and accelerate the body's natural healing processes. Its lead candidate, TR-987, is being developed for the treatment of chronic wounds, such as venous leg ulcers, and for use in post-procedural recovery following aesthetic treatments. By targeting the inflammatory phase of wound healing, the technology aims to improve clinical outcomes and reduce recovery times. The company focuses on addressing unmet needs in both the medical wound care and cosmetic dermatology markets through its specialized biological platform.

Recent filings

Filing Released Lang Actions
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 460.0KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement dated 31 July 2023, titled "Tissue Repair June 2023 Appendix 4C". It provides a quarterly update on the company's progress, including operational updates, financial cash flow data, and development milestones. The Appendix 4C is a standard quarterly cash flow report required by the ASX Listing Rule 4.7B for entities listed on the ASX. The document contains detailed financial data for the quarter ended 30 June 2023, including cash flows from operating and investing activities, and commentary on the use of funds and corporate updates. This matches the characteristics of an Interim / Quarterly Report (IR), as it is a comprehensive financial report for a period shorter than a full fiscal year, containing substantive financial data and analysis. It is not merely an announcement of a report or a certification, but the actual quarterly report itself. Therefore, the correct classification is IR (Interim / Quarterly Report).
2023-07-30 English
Change of Company Secretary 1 page 170.0KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 28/06/2023 regarding a change in the company's Company Secretary. It references compliance with ASX Listing Rules and details the appointment of a new Company Secretary and the stepping down of the previous one. There is no financial data, report, or presentation included. The content clearly relates to a change in senior management position, specifically the Company Secretary role, which falls under Board/Management Information filings.
2023-06-27 English
Change of Director's Interest Notice - JL 2 pages 5.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director's Interest Notice' and details changes in securities holdings by a company director, including dates, number of shares acquired, and nature of the transactions. It references ASX listing rules and the Corporations Act, indicating it is a regulatory disclosure of insider trading by a director. The content is focused on personal share transactions by a company director, which matches the definition of 'Director's Dealing'. The document length is short and specific to director's interest changes, not a broader financial or management report.
2023-06-05 English
FDA clears TR-987 to progress to Phase 3 2 pages 187.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 29/05/2023 regarding the FDA clearance for Tissue Repair Limited to progress into a Phase 3 clinical program for its lead drug candidate TR-987®. It discusses the completion of the End of Phase 2 meeting with the FDA, plans for Phase 3 trials, and funding status. The content is an update on clinical trial progress and regulatory interactions, not a full financial report or detailed financial statements. The document length is 3887 characters, which is relatively short and typical for an announcement. There is no detailed financial data, no earnings figures, no management discussion of financial results, nor is it a transcript or proxy material. It is clearly an announcement about a clinical development milestone and regulatory progress. Therefore, the most appropriate classification is a Regulatory Filing (RNS), as it is a general regulatory announcement that does not fit into other specific categories like Annual Report, Earnings Release, or Investor Presentation.
2023-05-28 English
Notification of cessation of securities - TRP 4 pages 24.4KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the lapse of certain options (securities) for Tissue Repair Ltd. It provides specific information about the securities that have ceased, including ASX security codes, number of securities ceased, reasons for cessation, and the updated issued capital following these changes. The document is an announcement about changes in the company's issued securities, specifically the cessation of certain options due to conditions not being met. It does not contain financial statements, management discussion, or detailed financial results. It is not a report but an official notification of changes in securities. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes such as cessation or lapse of securities.
2023-05-16 English
Initial Director's Interest Notice - MS 2 pages 182.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the appointment of a new director, Michael Silberberg, and discloses his relevant interests in securities and contracts, including unlisted options under the company's Long Term Incentive Plan. The content focuses on the director's personal share transactions and interests rather than financial results, governance policies, or other corporate filings. The document length is 2655 characters, which is consistent with a director's dealing notice rather than a full report or announcement. Therefore, this document fits the definition of a Director's Dealing report.
2023-05-01 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.